(VIANEWS) – HIGH CO (HCO.PA), FDJ (FDJ.PA), UCB (UCB.BR) are the highest payout ratio stocks on this list.
We have collected information concerning stocks with the highest payout ratio up until now. The payout ratio in itself isn’t a promise of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. HIGH CO (HCO.PA)
210.53% Payout Ratio
High Co. SA provides marketing solutions to various retailers and brands worldwide. The company offers brand platform, communication strategy, social media engagement, and media strategy services; and service design services, SMS and push notifications, mobile applications and websites, and loyalty programs. It also provides data collection and analysis, targeting and personalization drivers, predictive algorithms, and GDPR compliant technologies; and promotion mechanics, multi-channel distribution, logistics and merchandising, and operational management and coupon processing services. The company was founded in 1990 and is headquartered in Aix-en-Provence, France.
Earnings Per Share
As for profitability, HIGH CO has a trailing twelve months EPS of €0.19.
PE Ratio
HIGH CO has a trailing twelve months price to earnings ratio of 22.37. Meaning, the purchaser of the share is investing €22.37 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.99%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.1%, now sitting on 150.08M for the twelve trailing months.
Moving Average
HIGH CO’s worth is under its 50-day moving average of €4.60 and way under its 200-day moving average of €4.85.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on May 24, 2023, the estimated forward annual dividend rate is 0.4 and the estimated forward annual dividend yield is 9.3%.
More news about HIGH CO.
2. FDJ (FDJ.PA)
79.52% Payout Ratio
La Française des Jeux Société anonyme operates lottery, and online and PoS sports betting games in France and internationally. The company offers instant and draw games, as well as online poker. It also provides risk management services for sports betting operators; and operates a digital gaming platform. The company was founded in 1933 and is headquartered in Boulogne-Billancourt, France.
Earnings Per Share
As for profitability, FDJ has a trailing twelve months EPS of €1.72.
PE Ratio
FDJ has a trailing twelve months price to earnings ratio of 18.91. Meaning, the purchaser of the share is investing €18.91 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 41.09%.
Moving Average
FDJ’s value is above its 50-day moving average of €31.46 and below its 200-day moving average of €35.65.
More news about FDJ.
3. UCB (UCB.BR)
78.24% Payout Ratio
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, China, Italy, the United Kingdom, Ireland, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Earnings Per Share
As for profitability, UCB has a trailing twelve months EPS of €1.7.
PE Ratio
UCB has a trailing twelve months price to earnings ratio of 39.59. Meaning, the purchaser of the share is investing €39.59 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.7%.
Moving Average
UCB’s value is way under its 50-day moving average of €76.76 and way below its 200-day moving average of €80.57.
Volume
Today’s last reported volume for UCB is 100043 which is 59.28% below its average volume of 245685.
Revenue Growth
Year-on-year quarterly revenue growth declined by 11.8%, now sitting on 5.11B for the twelve trailing months.
More news about UCB.
4. SPAREBANK 1 SØRØ (SOON.OL)
49.24% Payout Ratio
SpareBank 1 Sørøst-Norge provides various banking products and services for private and corporate customers in Norway. The company offers mobile and online banking, card, account, and payment services. It also provides mortgage, car, boat, consumer, and other vehicle loans as well as refinancing, micro savings, investment, pension, and property related services. In addition, the company offers daily operations, get paid, loans and financing, and pension related products. Further, it provides business and personnel insurance as well as savings and investment products. The company was founded in 1859 and is headquartered in Sandefjord, Norway.
Earnings Per Share
As for profitability, SPAREBANK 1 SØRØ has a trailing twelve months EPS of kr5.59.
PE Ratio
SPAREBANK 1 SØRØ has a trailing twelve months price to earnings ratio of 10.38. Meaning, the purchaser of the share is investing kr10.38 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.74%.
More news about SPAREBANK 1 SØRØ.
5. TUBIZE-FIN (TUB.BR)
43.03% Payout Ratio
Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.
Earnings Per Share
As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €2.
PE Ratio
TUBIZE-FIN has a trailing twelve months price to earnings ratio of 31.25. Meaning, the purchaser of the share is investing €31.25 for every euro of annual earnings.
Yearly Top and Bottom Value
TUBIZE-FIN’s stock is valued at €62.50 at 01:10 EST, way under its 52-week high of €79.90 and above its 52-week low of €60.80.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on May 3, 2023, the estimated forward annual dividend rate is 0.86 and the estimated forward annual dividend yield is 1.29%.
Volume
Today’s last reported volume for TUBIZE-FIN is 2031 which is 73.02% below its average volume of 7530.
Moving Average
TUBIZE-FIN’s worth is below its 50-day moving average of €67.67 and way below its 200-day moving average of €72.39.
More news about TUBIZE-FIN.
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of €1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing €1 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 1% and 1%, respectively.
Volatility
1’s last week, last month’s, and last quarter’s current intraday variation average was 1.00%, 1.00%, and 1.00%.
1’s highest amplitude of average volatility was 1.00% (last week), 1.00% (last month), and 1.00% (last quarter).
Revenue Growth
Year-on-year quarterly revenue growth grew by 1%, now sitting on 1 for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
1’s EBITDA is 1.
More news about 1.
